BCAB Stock Overview
A clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
BioAtla, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.07 |
| 52 Week High | US$4.02 |
| 52 Week Low | US$1.14 |
| Beta | 1.05 |
| 11 Month Change | -5.91% |
| 3 Month Change | 48.92% |
| 1 Year Change | 17.61% |
| 33 Year Change | -92.86% |
| 5 Year Change | n/a |
| Change since IPO | -93.33% |
Recent News & Updates
BioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative Buy
Oct 08We're A Little Worried About BioAtla's (NASDAQ:BCAB) Cash Burn Rate
Jul 16
Recent updates
BioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative Buy
Oct 08We're A Little Worried About BioAtla's (NASDAQ:BCAB) Cash Burn Rate
Jul 16BioAtla: A Buried ADC Concern Gets Some New Life In 2024
May 02Will BioAtla (NASDAQ:BCAB) Spend Its Cash Wisely?
Mar 14Is BioAtla (NASDAQ:BCAB) In A Good Position To Deliver On Growth Plans?
Nov 05We Think BioAtla (NASDAQ:BCAB) Needs To Drive Business Growth Carefully
Jun 27Will BioAtla (NASDAQ:BCAB) Spend Its Cash Wisely?
Mar 24BioAtla (NASDAQ:BCAB) Is In A Good Position To Deliver On Growth Plans
Sep 27BioAtla: Back From The Dead
Sep 23BioAtla: Promising Signal In NSCLC, But Concerns Remain
Aug 23BioAtla reports Q2 results
Aug 09We're Keeping An Eye On BioAtla's (NASDAQ:BCAB) Cash Burn Rate
May 11Companies Like BioAtla (NASDAQ:BCAB) Are In A Position To Invest In Growth
Jan 06BioAtla (NASDAQ:BCAB) Is In A Good Position To Deliver On Growth Plans
Jul 24Are Insiders Buying BioAtla, Inc. (NASDAQ:BCAB) Stock?
Mar 16Shareholder Returns
| BCAB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.0% | 0.6% | -0.8% |
| 1Y | 17.6% | 21.4% | 31.5% |
Return vs Industry: BCAB underperformed the US Biotechs industry which returned 20.2% over the past year.
Return vs Market: BCAB underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| BCAB volatility | |
|---|---|
| BCAB Average Weekly Movement | 12.5% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: BCAB's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: BCAB's weekly volatility has decreased from 18% to 12% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 65 | Jay Short | www.bioatla.com |
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company’s lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types.
BioAtla, Inc. Fundamentals Summary
| BCAB fundamental statistics | |
|---|---|
| Market cap | US$96.67m |
| Earnings (TTM) | -US$104.56m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.0x
P/E RatioIs BCAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BCAB income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$86.12m |
| Gross Profit | -US$86.12m |
| Other Expenses | US$18.43m |
| Earnings | -US$104.56m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 07, 2024
| Earnings per share (EPS) | -2.16 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did BCAB perform over the long term?
See historical performance and comparison